MINNEAPOLIS, Aug. 7, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
reported its financial results for the fourth quarter ending
June 30, 2024.
Fourth Quarter FY2024 Highlights
- Fourth quarter organic revenue increased by 1% (2% reported) to
$306.1 million. Full year organic
revenue increased 1% (2% reported) to $1.2
billion.
- GAAP earnings per share (EPS) was $0.25 versus $0.47
one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was
$1.05 versus $1.76 one year ago. Full year adjusted EPS was
$1.77 versus $1.99 one year ago.
- Strong commercial execution in Diagnostics & Genomics led
to 9% organic segment growth (15% reported) in the fourth quarter
and 6% organic segment growth (12% reported) for fiscal year
2024.
- Fiscal year 2024 cash flow generated from operations increased
to $299.0 million, an 18% increase
from the prior year.
The Company's financial statements are prepared in accordance
with accounting principles generally accepted in the United States (GAAP). Adjusted diluted
EPS, adjusted net earnings, adjusted gross margin, adjusted
operating income, adjusted tax rate, organic revenue, adjusted
operating margin, earnings before interest, taxes, depreciation,
and amortization (EBITDA), and adjusted EBITDA are non-GAAP
measures that exclude certain items detailed later in this press
release under the heading "Use of non-GAAP Adjusted Financial
Measures." A reconciliation of GAAP to non-GAAP financial measures
is included in this press release.
"I am extremely proud of our team's dedication and execution in
stabilizing, yet still challenging end-markets." said Kim Kelderman, President and Chief Executive
Officer of Bio-Techne. "We achieved another quarter of solid
financial results while experiencing continued stabilization in
both our biopharma and China
end-markets, and strong performance in our diagnostic product
businesses. We delivered this top-line result with a continued
focus on profitability, which resulted in a 33.5% adjusted
operating margin, representing a 50 basis-point sequential
improvement."
Kelderman added, "Our differentiated financial performance
throughout fiscal 2024 showcases the value our growth pillars, as
well as our core portfolio, bring to our customers, even when
budgets are constrained. This gives us confidence in continued
outperformance while life science research end-markets return to
historical growth rates."
Bio-Techne will host an earnings conference call today,
August 7, 2024 at 8:00 a.m. CDT. To listen, please dial
1-800-343-4136 or 1-203-518-9843 (for international callers), and
reference conference ID BioTechne. The earnings call can also be
accessed via webcast through the following link
https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties
unable to participate in the live conference call by dialing
1-844-512- 2921 or 1-412-317-6671 (for international callers) and
referencing Conference ID 11156560. The replay will be available
from 11:00 a.m. CDT on Wednesday,
August 7, 2024, until 11:00 p.m. CDT on Saturday, September 7, 2024.
Fourth Quarter Fiscal 2024
Revenue
Net sales for the fourth quarter increased 2% to $306.1 million. Organic revenue increased 1%
compared to the prior year, with acquisitions contributing 1%.
Foreign currency exchange and a business held-for-sale did not have
a material impact.
GAAP Earnings Results
GAAP EPS was $0.25 per diluted
share, versus $0.47 in the same
quarter last year. GAAP operating income for the fourth quarter of
fiscal 2024 decreased 52% to $45.8
million, compared to $94.5
million in the fourth quarter of fiscal 2023. GAAP operating
margin was 15.0%, compared to 31.4% in the fourth quarter of fiscal
2023. Current year GAAP operating margin was impacted by impairment
of assets held-for-sale, restructuring and CEO transition costs,
certain litigation charges, changes in the fair value of
performance-based stock compensation awards in the prior year, and
the acquisition of Lunaphore.
Non-GAAP Earnings Results
Adjusted EPS decreased to $0.49
per diluted share compared to $0.55
in the same quarter last year. Adjusted operating income for the
fourth quarter of fiscal 2024 decreased 9% to $101.8 million, compared to $111.8 million in the fourth quarter of fiscal
2023. Adjusted operating margin was 33.5%, compared to 37.1% in the
fourth quarter of fiscal 2023. Adjusted operating margin was
unfavorably impacted by the acquisition of Lunaphore and
unfavorable volume leverage within Protein Sciences.
Full Year Fiscal 2024
Revenue
Net sales for the full year fiscal 2024 increased 2% to
$1.2 billion. Organic revenue
increased 1%, with acquisitions contributing 1%. Foreign currency
exchange and a business held-for-sale did not have a material
impact.
GAAP Earnings Results
GAAP EPS was $1.05 per diluted
share, compared to $1.76 last fiscal
year. GAAP operating income for full year fiscal 2024 decreased 31%
to $206.7 million, compared to
$298.9 million in the full year
fiscal 2023. GAAP operating margin was 17.8%, compared to 26.3% in
the full year fiscal 2023. GAAP operating margin was impacted by
impairment of assets held-for-sale, restructuring and CEO
transition costs, certain litigation charges, non-recurring benefit
related to the fair value of contingent consideration in the prior
year, the acquisition of Lunaphore, and unfavorable volume leverage
within Protein Sciences.
Non-GAAP Earnings Results
Adjusted EPS decreased to $1.77
per diluted share, compared to $1.99
last fiscal year. Adjusted operating income for fiscal 2024
decreased 10% to $370.2 million,
compared to $410.2 million for fiscal
2023. Adjusted operating margin for full year fiscal 2024 decreased
to 32.1%, compared to 36.1% in full year fiscal 2023. Adjusted
operating margin was unfavorably impacted by the acquisition of
Lunaphore and unfavorable volume leverage within Protein
Sciences.
Segment Results
Management uses adjusted operating results to monitor and
evaluate performance of the Company's business segments, as
highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's
leading suppliers of specialized proteins such as cytokines and
growth factors, immunoassays, antibodies and reagents, to the
biotechnology and academic research communities. Additionally, the
segment provides an array of platforms useful in various areas of
protein analysis. Protein Sciences segment's fourth quarter fiscal
2024 net sales were $214.0 million, a
decrease of 4% from $223.0 million
for the fourth quarter of fiscal 2023. As of December 31, 2023, a business within the Protein
Sciences Segment met the criteria as held-for-sale; this
held-for-sale business has been excluded from the segment's third
and fourth quarter fiscal operating results. The exclusion of
fourth quarter of fiscal 2024 sales related to this held-for-sale
business reduced sales by 1%. Organic revenue for the segment
declined 3% and foreign currency exchange did not have a material
impact. The Protein Sciences segment's operating margin was 43.0%
in the fourth quarter of fiscal 2024 compared to 44.7% in the
fourth quarter of fiscal 2023. The segment's operating margin
decreased primarily due to unfavorable volume leverage.
Protein Sciences segment's full year fiscal 2024 net sales were
$830.9 million, a decrease of 2% from
$845.7 million for full year fiscal
2023. As noted above, a business within the Protein Sciences
Segment met the criteria as held-for-sale since December 31, 2023. The exclusion of third and
fourth quarter of fiscal 2024 sales related to a held-for-sale
business reduced sales by 1%. Organic revenue for the segment
declined 2% for the fiscal year, with foreign currency exchange
having a favorable 1% impact on revenue. Protein Sciences segment's
operating margin was 42.7% in fiscal 2024 compared to 44.2% in
fiscal 2023. The segment's operating margin decreased primarily due
to unfavorable volume leverage.
Diagnostics and Genomics Segment
The Company's Diagnostics and Genomics segment develops and
provides spatial biology products as well as exosome-based
diagnostics for various pathologies, including prostate cancer. The
Diagnostics and Genomics segment also provides blood chemistry and
blood gas quality controls, hematology instrument controls,
immunoassays and other bulk and custom reagents for the in vitro
diagnostic market. The Diagnostics and Genomics segment's fourth
quarter fiscal 2024 net sales were $90.7
million, an increase of 15% from $79.0 million for the fourth quarter of fiscal
2023. Organic revenue growth was 9% for the fourth quarter of
fiscal 2024, with acquisitions having a 6% impact and foreign
exchange not having a material impact. The Diagnostics and Genomics
segment's operating margin was 12.5% in the fourth quarter of
fiscal 2024 compared to 18.5% in the fourth quarter of fiscal 2023.
The segment's operating margin decreased primarily due to the
Lunaphore acquisition.
The Diagnostics and Genomics segment's full year fiscal 2024 net
sales were $326.4 million, an
increase of 12% from $292.6 million
for full year fiscal 2023. Organic growth for the segment was 6%
with acquisitions having a 5% impact and foreign currency exchange
having a favorable impact of 1% on revenue growth. The Diagnostics
and Genomics segment's operating margin was 7.5% in fiscal 2024
compared to 14.7% in fiscal 2023. The segment's operating margin
decreased due to strategic growth investments and the Lunaphore
acquisition partially offset by favorable volume leverage.
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not
been calculated in accordance with accounting principles generally
accepted in the U.S. These non-GAAP measures include:
- Organic revenue
- Adjusted diluted earnings per share
- Adjusted net earnings
- Adjusted tax rate
- Adjusted gross margin
- Adjusted operating income
- Adjusted operating margin
- Earnings before interest, taxes, depreciation, and amortization
(EBITDA)
- Adjusted EBITDA
We provide these measures as additional information regarding
our operating results. We use these non-GAAP measures internally to
evaluate our performance and in making financial and operational
decisions, including with respect to incentive compensation. We
believe that our presentation of these measures provides investors
with greater transparency with respect to our results of operations
and that these measures are useful for period-to-period comparison
of results.
Our non-GAAP financial measure of organic revenue represents
revenue growth excluding revenue from acquisitions within the
preceding 12 months, the impact of foreign currency, the impact of
businesses held-for-sale, as well as the impact of partially-owned
consolidated subsidiaries. Excluding these measures provides more
useful period-to-period comparison of revenue results as it
excludes the impact of foreign currency exchange rates, which can
vary significantly from period to period, and revenue from
acquisitions that would not be included in the comparable prior
period. Revenues from businesses held-for-sale are excluded from
our organic revenue calculation starting on the date they become
held-for-sale as those revenues will not be comparative in
future periods. Revenues from partially-owned subsidiaries
consolidated in our financial statements are also excluded from our
organic revenue calculation, as those revenues are not fully
attributable to the Company. There was no revenue from
partially-owned consolidated subsidiaries in fiscal year 2024 due
to the sale of Changzhou Eminence Biotechnology Co., Ltd.
(Eminence) in the first quarter of fiscal 2023. Revenue from
partially-owned consolidated subsidiaries was $2.0 million for the year ended June 30, 2023.
Our non-GAAP financial measures for adjusted gross margin,
adjusted operating margin, adjusted EBITDA, and adjusted net
earnings, in total and on a per share basis, exclude stock-based
compensation, which is inclusive of the employer portion of payroll
taxes on those stock awards, the costs recognized upon the sale of
acquired inventory, amortization of acquisition intangibles,
restructuring and restructuring-related costs, and other
non-recurring items including non-recurring costs, goodwill and
long-lived asset impairments, and gains. Stock-based compensation
is excluded from non-GAAP adjusted net earnings because of the
nature of this charge, specifically the varying available valuation
methodologies, subjection assumptions, variety of award types, and
unpredictability of amount and timing of employer related tax
obligations. The Company excludes amortization of purchased
intangible assets, purchase accounting adjustments, including costs
recognized upon the sale of acquired inventory and
acquisition-related expenses inclusive of the changes in fair value
contingent consideration, and other non-recurring items including
gains or losses on goodwill and long-lived asset impairment
charges, and one-time assessments from this measure because they
occur as a result of specific events, and are not reflective of our
internal investments, the costs of developing, producing,
supporting and selling our products, and the other ongoing costs to
support our operating structure. We also exclude certain litigation
charges which are facts and circumstances specific including costs
to resolve litigation and legal settlement (gains and losses). In
some cases, these costs may be a result of litigation matters at
acquired companies that were not probable, inestimable, or
unresolved at the time of acquisition. Costs related to
restructuring and restructuring-related activities, including
reducing overhead and consolidating facilities, are excluded
because we believe they are not indicative of our normal operating
costs. Additionally, these amounts can vary significantly
from period to period based on current activity. The Company also
excludes revenue and expense attributable to partially-owned
consolidated subsidiaries as well as revenue and expense
attributable to businesses held-for-sale in the calculation of our
non-GAAP financial measures.
The Company's non-GAAP adjusted operating margin and adjusted
net earnings, in total and on a per share basis, also excludes
acquisition related expenses inclusive of the changes in fair value
of contingent consideration, gain and losses from investments, as
they are not part of our day-to-day operating decisions (excluding
our equity method investment in Wilson
Wolf as it is certain to be acquired in the future), certain
adjustments to income tax expense, and other non-recurring items
including certain costs related to the transition to a new CEO.
Additionally, gains and losses from investments that are either
isolated or cannot be expected to occur again with any
predictability are excluded. The Company independently calculates a
non-GAAP adjusted tax rate to be applied to the identified non-GAAP
adjustments considering the impact of discrete items on these
adjustments and the jurisdictional mix of the adjustments. In
addition, the tax impact of other discrete and non-recurring
charges which impact our reported GAAP tax rate are adjusted from
net earnings. We believe these tax items can significantly affect
the period-over-period assessment of operating results and not
necessarily reflect costs and/or income associated with historical
trends and future results.
Investors are encouraged to review the reconciliations of
adjusted financial measures used in this press release to their
most directly comparable GAAP financial measures as provided with
the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act. Such
statements involve risks and uncertainties that may affect the
actual results of operations. The following important factors,
among others, have affected and, in the future, could affect the
Company's actual results: the effect of new branding and marketing
initiatives, the integration of new businesses and leadership, the
introduction and acceptance of new products, the funding and focus
of the types of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products
and related price competition, general economic conditions,
customer site closures or supply chain issues, the impact of
currency exchange rate fluctuations, and the costs and results of
research and product development efforts of the Company and of
companies in which the Company has invested or with which it has
formed strategic relationships.
For additional information concerning such factors, see the
section titled "Risk Factors" in the Company's annual report on
Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statements we make in our
press releases due to new information or future events. Investors
are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $1.2
billion in net sales in fiscal 2024 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit www.biotechne.com.
Contact:
|
David Clair, Vice
President, Investor Relations & Corporate
Development
|
|
David.Clair@bio-techne.com
|
|
612-656-4416
|
BIO-TECHNE CORPORATION
|
CONSOLIDATED STATEMENTS
OF EARNINGS
|
(In thousands, except
per share data)
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Net Sales
|
|
$
|
306,098
|
|
$
|
301,320
|
|
$
|
1,159,060
|
|
$
|
1,136,702
|
Cost of
sales
|
|
|
102,751
|
|
|
96,623
|
|
|
389,335
|
|
|
366,887
|
Gross margin
|
|
|
203,347
|
|
|
204,697
|
|
|
769,725
|
|
|
769,815
|
Operating
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and
administrative
|
|
|
133,536
|
|
|
86,754
|
|
|
466,375
|
|
|
378,378
|
Research and
development
|
|
|
23,989
|
|
|
23,418
|
|
|
96,664
|
|
|
92,493
|
Total Operating
Expenses
|
|
|
157,525
|
|
|
110,172
|
|
|
563,039
|
|
|
470,871
|
Operating
income
|
|
|
45,822
|
|
|
94,525
|
|
|
206,686
|
|
|
298,944
|
Other income
(expense)
|
|
|
(4,162)
|
|
|
(6,209)
|
|
|
(20,997)
|
|
|
39,715
|
Earnings before income
taxes
|
|
|
41,660
|
|
|
88,316
|
|
|
185,689
|
|
|
338,659
|
Income taxes
|
|
|
1,073
|
|
|
12,832
|
|
|
17,584
|
|
|
53,217
|
Net earnings, including
noncontrolling interest
|
|
$
|
40,587
|
|
$
|
75,484
|
|
$
|
168,105
|
|
$
|
285,442
|
Net earnings
attributable to noncontrolling interest
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
179
|
Net earnings
attributable to Bio-Techne
|
|
$
|
40,587
|
|
$
|
75,484
|
|
$
|
168,105
|
|
$
|
285,263
|
Earnings per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.26
|
|
$
|
0.48
|
|
$
|
1.07
|
|
$
|
1.81
|
Diluted
|
|
$
|
0.25
|
|
$
|
0.47
|
|
$
|
1.05
|
|
$
|
1.76
|
Weighted average common
shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
157,868
|
|
|
157,504
|
|
|
157,708
|
|
|
157,179
|
Diluted
|
|
|
160,651
|
|
|
161,920
|
|
|
160,774
|
|
|
161,855
|
BIO-TECHNE CORPORATION
|
CONSOLIDATED CONDENSED
BALANCE SHEETS
|
(In
thousands)
|
(Unaudited)
|
|
|
|
6/30/2024
|
|
6/30/2023
|
ASSETS
|
|
|
|
|
|
|
Cash and
equivalents
|
|
$
|
151,791
|
|
$
|
180,571
|
Short-term
available-for-sale investments
|
|
|
1,072
|
|
|
23,739
|
Accounts receivable,
net
|
|
|
241,394
|
|
|
218,468
|
Inventories
|
|
|
179,731
|
|
|
171,638
|
Current assets
held-for-sale
|
|
|
9,773
|
|
|
—
|
Other current
assets
|
|
|
33,658
|
|
|
27,066
|
Total current
assets
|
|
|
617,419
|
|
|
621,482
|
|
|
|
|
|
|
|
Property and equipment,
net
|
|
|
251,154
|
|
|
226,200
|
Right of use
assets
|
|
|
91,285
|
|
|
98,326
|
Goodwill and intangible
assets, net
|
|
|
1,479,744
|
|
|
1,407,382
|
Other assets
|
|
|
264,265
|
|
|
285,302
|
Total assets
|
|
$
|
2,703,867
|
|
$
|
2,638,692
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
Accounts payable and
accrued expenses
|
|
$
|
112,672
|
|
$
|
77,306
|
Contract
liabilities
|
|
|
27,930
|
|
|
23,069
|
Income taxes
payable
|
|
|
3,706
|
|
|
12,022
|
Contingent
consideration payable
|
|
|
—
|
|
|
3,500
|
Operating lease
liabilities - current
|
|
|
12,920
|
|
|
11,199
|
Other current
liabilities
|
|
|
2,151
|
|
|
1,413
|
Total current
liabilities
|
|
|
159,379
|
|
|
128,509
|
|
|
|
|
|
|
|
Deferred income
taxes
|
|
|
55,863
|
|
|
88,982
|
Long-term debt
obligations
|
|
|
319,000
|
|
|
350,000
|
Operating lease
liabilities
|
|
|
87,618
|
|
|
93,766
|
Other long-term
liabilities
|
|
|
13,157
|
|
|
10,919
|
Stockholders'
equity
|
|
|
2,068,850
|
|
|
1,966,516
|
Total liabilities and
stockholders' equity
|
|
$
|
2,703,867
|
|
$
|
2,638,692
|
BIO-TECHNE CORPORATION
|
RECONCILIATION OF
ADJUSTED GROSS MARGIN PERCENTAGE
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Gross margin percentage
- GAAP
|
|
66.4
|
%
|
|
67.9
|
%
|
|
66.4
|
%
|
|
67.7
|
%
|
Identified
adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs recognized upon
sale of acquired inventory
|
|
0.1
|
%
|
|
—
|
%
|
|
0.1
|
%
|
|
0.0
|
%
|
Amortization of
intangibles
|
|
3.9
|
%
|
|
3.7
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
Stock compensation
expense - COGS
|
|
0.1
|
%
|
|
0.0
|
%
|
|
0.1
|
%
|
|
0.1
|
%
|
Restructuring and
restructuring-related costs
|
|
0.5
|
%
|
|
—
|
%
|
|
0.3
|
%
|
|
—
|
%
|
Impact of
partially-owned consolidated subsidiaries1)
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
(0.1)
|
%
|
Impact of business
held-for-sale2)
|
|
0.1
|
%
|
|
—
|
%
|
|
0.1
|
%
|
|
—
|
%
|
Gross margin percentage
- Adjusted
|
|
71.1
|
%
|
|
71.6
|
%
|
|
71.0
|
%
|
|
71.7
|
%
|
|
1) Includes the quarterly results of
the partially-owned consolidated subsidiary prior to the sale of
this partially-owned consolidated subsidiary to a third party in
the first fiscal quarter of 2023.
|
2) Since
December 31, 2023, the Company has a business that has met the
held-for-sale criteria. For the quarter ended June 30, 2024,
includes the results for the three-months ended for this business
held-for-sale. For the year ended June 30, 2024, includes the
six-month results of this business held-for-sale for the period
starting December 31, 2023 through June 30, 2024 while the business
has met the held-for-sale criteria.
|
BIO-TECHNE CORPORATION
|
RECONCILIATION OF
ADJUSTED OPERATING MARGIN PERCENTAGE
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Operating margin
percentage - GAAP
|
|
15.0
|
%
|
|
31.4
|
%
|
|
17.8
|
%
|
|
26.3
|
%
|
Identified
adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs recognized upon
sale of acquired inventory
|
|
0.1
|
%
|
|
—
|
%
|
|
0.1
|
%
|
|
0.0
|
%
|
Amortization of
intangibles
|
|
6.3
|
%
|
|
6.2
|
%
|
|
6.8
|
%
|
|
6.7
|
%
|
Acquisition related
expenses and other
|
|
1.5
|
%
|
|
(0.2)
|
%
|
|
0.6
|
%
|
|
(0.8)
|
%
|
Certain litigation
charges
|
|
1.2
|
%
|
|
—
|
%
|
|
0.3
|
%
|
|
—
|
%
|
Stock-based
compensation, inclusive of employer taxes
|
|
2.4
|
%
|
|
(0.6)
|
%
|
|
3.5
|
%
|
|
3.6
|
%
|
Restructuring and
restructuring-related costs
|
|
1.7
|
%
|
|
0.3
|
%
|
|
1.1
|
%
|
|
0.3
|
%
|
Impairment of assets
held-for-sale
|
|
5.2
|
%
|
|
—
|
%
|
|
1.9
|
%
|
|
—
|
%
|
Impact of
partially-owned consolidated subsidiaries1)
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
0.0
|
%
|
Impact of business
held-for-sale2)
|
|
0.1
|
%
|
|
—
|
%
|
|
0.0
|
%
|
|
—
|
%
|
Operating margin
percentage - Adjusted
|
|
33.5
|
%
|
|
37.1
|
%
|
|
32.1
|
%
|
|
36.1
|
%
|
|
1) Includes the quarterly results of
the partially-owned consolidated subsidiary prior to the sale of
this partially-owned consolidated subsidiary to a third party in
the first fiscal quarter of 2023. As disclosed in our use of
Non-GAAP Adjusted Financial Measures, the adjusted operating margin
percentages excludes partially-owned consolidated revenue and
expense amounts. Due to the sale of this partially-owned
consolidated subsidiary in the first fiscal quarter of 2023, there
was no impact on operating margin for the quarter and year ended
June 30, 2024 and the quarter ended June 30, 2023. The excluded
revenue and excluded operating income attributable to
partially-owned consolidated subsidiaries had a 0.1% and
(0.1)% impact, respectively, on the operating margin for full year
fiscal 2023.
|
2) Since December 31, 2023, the
Company has a business that has met the held-for-sale criteria. For
the quarter ended June 30, 2024, includes the results for the
three-months ended for this business held-for-sale. For the year
ended June 30, 2024, includes the six-month results of this
business held-for-sale for the period starting December 31, 2023
through June 30, 2024 while the business has met the held-for-sale
criteria.
|
BIO-TECHNE CORPORATION
|
NON-GAAP ADJUSTED
CONSOLIDATED NET EARNINGS and EARNINGS per SHARE
|
(In thousands, except
per share data) (Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
|
ENDED
|
|
ENDED
|
|
|
|
6/30/2024
|
|
6/30/2023
|
|
|
6/30/2024
|
|
6/30/2023
|
|
Net earnings before
taxes - GAAP
|
|
$
|
41,660
|
|
$
|
88,316
|
|
|
$
|
185,689
|
|
$
|
338,659
|
|
Identified adjustments
attributable to Bio-Techne:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs recognized upon
sale of acquired inventory
|
|
|
179
|
|
|
—
|
|
|
|
729
|
|
|
400
|
|
Amortization of
intangibles
|
|
|
19,411
|
|
|
18,719
|
|
|
|
78,318
|
|
|
76,413
|
|
Amortization of Wilson
Wolf intangible assets and acquired inventory
|
|
|
3,062
|
|
|
2,805
|
|
|
|
15,686
|
|
|
2,805
|
|
Acquisition related
expenses and other
|
|
|
4,955
|
|
|
(477)
|
|
|
|
7,564
|
|
|
(9,147)
|
|
Certain litigation
charges
|
|
|
3,506
|
|
|
—
|
|
|
|
3,506
|
|
|
—
|
|
Gain on sale of
partially-owned consolidated subsidiaries
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
(11,682)
|
|
Stock-based
compensation, inclusive of employer taxes
|
|
|
7,466
|
|
|
(1,662)
|
|
|
|
40,277
|
|
|
41,217
|
|
Restructuring and
restructuring-related costs
|
|
|
5,087
|
|
|
879
|
|
|
|
12,245
|
|
|
3,829
|
|
Investment (gain) loss
and other non-operating
|
|
|
0
|
|
|
682
|
|
|
|
(283)
|
|
|
(37,646)
|
|
Impairment of assets
held-for-sale
|
|
|
15,926
|
|
|
—
|
|
|
|
21,963
|
|
|
—
|
|
Impact of
partially-owned consolidated subsidiaries1)
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
(420)
|
|
Impact of business
held-for-sale(2)
|
|
|
(447)
|
|
|
—
|
|
|
|
(525)
|
|
|
—
|
|
Net earnings before
taxes - Adjusted1,2)
|
|
$
|
100,805
|
|
$
|
109,262
|
|
|
$
|
365,169
|
|
$
|
404,428
|
|
Non-GAAP tax
rate
|
|
|
22.0
|
%
|
|
19.2
|
%
|
|
|
22.0
|
%
|
|
20.5
|
%
|
Non-GAAP tax
expense
|
|
$
|
22,239
|
|
$
|
20,962
|
|
|
$
|
80,420
|
|
$
|
82,948
|
|
Non-GAAP adjusted net
earnings attributable to Bio-Techne1,2)
|
|
$
|
78,566
|
|
$
|
88,300
|
|
|
$
|
284,749
|
|
$
|
321,480
|
|
Earnings per share -
diluted - Adjusted1,2)
|
|
$
|
0.49
|
|
$
|
0.55
|
|
|
$
|
1.77
|
|
$
|
1.99
|
|
|
1) Includes
the quarterly results of the partially-owned consolidated
subsidiary prior to the sale of this partially-owned consolidated
subsidiary to a third party in the first fiscal quarter of
2023.
|
2) Since December 31, 2023, the
Company has a business that has met the held-for-sale criteria. For
the quarter ended June 30, 2024, includes the results for the
three-months ended for this business held-for-sale. For the year
ended June 30, 2024, includes the six-month results of this
business held-for-sale for the period starting December 31, 2023
through June 30, 2024 while the business has met the held-for-sale
criteria.
|
BIO-TECHNE CORPORATION
|
NON-GAAP adjusted tax
rate (In percentages)
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
GAAP effective tax
rate
|
|
2.6
|
%
|
|
14.5
|
%
|
|
9.5
|
%
|
|
15.7
|
%
|
Discrete
items
|
|
20.0
|
|
|
3.0
|
|
|
14.0
|
|
|
3.4
|
|
Impact of non-taxable
net gain
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
Annual forecast
update
|
|
0.9
|
|
|
2.3
|
|
|
—
|
|
|
—
|
|
Long-term GAAP tax
rate
|
|
23.5
|
%
|
|
19.8
|
%
|
|
23.5
|
%
|
|
19.8
|
%
|
Rate impact
items
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based
compensation
|
|
(2.8)
|
%
|
|
0.5
|
%
|
|
(2.5)
|
%
|
|
(1.4)
|
%
|
Other
|
|
1.3
|
|
|
(1.1)
|
|
|
1.0
|
|
|
2.1
|
|
Total rate impact
items
|
|
(1.5)
|
%
|
|
(0.6)
|
%
|
|
(1.5)
|
%
|
|
0.7
|
%
|
Non-GAAP adjusted tax
rate
|
|
22.0
|
%
|
|
19.2
|
%
|
|
22.0
|
%
|
|
20.5
|
%
|
BIO-TECHNE CORPORATION
|
SEGMENT
REVENUE
|
(In
thousands)
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Protein Sciences
segment revenue
|
|
$
|
213,988
|
|
$
|
223,008
|
|
$
|
830,902
|
|
$
|
845,747
|
Diagnostics and
Genomics segment revenue
|
|
|
90,678
|
|
|
79,025
|
|
|
326,392
|
|
|
292,602
|
Other
revenue1)
|
|
|
2,060
|
|
|
—
|
|
|
4,153
|
|
|
—
|
lntersegment
revenue
|
|
|
(628)
|
|
|
(713)
|
|
|
(2,387)
|
|
|
(1,647)
|
Consolidated
revenue
|
|
$
|
306,098
|
|
$
|
301,320
|
|
$
|
1,159,060
|
|
$
|
1,136,702
|
|
1) Since
December 31, 2023, the Company has a business that has met the
held-for-sale criteria. For the quarter ended June 30, 2024,
includes the results for the three-months ended for this business
held-for-sale. For the year ended June 30, 2024, includes the
six-month results of this business held-for-sale for the period
starting December 31, 2023 through June 30, 2024 while the business
has met the held-for-sale criteria.
|
BIO-TECHNE CORPORATION
|
SEGMENT OPERATING
INCOME
|
(In
thousands)
|
(Unaudited)
|
|
|
|
QUARTER
|
|
YEAR
|
|
|
ENDED
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Protein Sciences
segment operating income
|
|
$
|
91,999
|
|
$
|
99,649
|
|
$
|
354,775
|
|
$
|
373,684
|
Diagnostics and
Genomics segment operating income
|
|
|
11,357
|
|
|
14,638
|
|
|
24,546
|
|
|
43,037
|
Segment operating
income
|
|
|
103,356
|
|
|
114,287
|
|
|
379,321
|
|
|
416,721
|
Corporate general,
selling, and administrative
|
|
|
(1,597)
|
|
|
(2,449)
|
|
|
(9,142)
|
|
|
(6,530)
|
Adjusted operating
income
|
|
|
101,759
|
|
|
111,838
|
|
|
370,179
|
|
|
410,191
|
Cost recognized upon
sale of acquired inventory
|
|
|
(179)
|
|
|
—
|
|
|
(729)
|
|
|
(400)
|
Amortization of
intangibles
|
|
|
(19,411)
|
|
|
(18,719)
|
|
|
(78,318)
|
|
|
(76,413)
|
Acquisition related
expenses and other
|
|
|
(4,809)
|
|
|
623
|
|
|
(6,980)
|
|
|
9,965
|
Certain litigation
charges
|
|
|
(3,506)
|
|
|
—
|
|
|
(3,506)
|
|
|
—
|
Impact of
partially-owned consolidated subsidiaries1)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
647
|
Stock-based
compensation, inclusive of employer taxes
|
|
|
(7,466)
|
|
|
1,662
|
|
|
(40,277)
|
|
|
(41,217)
|
Restructuring and
restructuring-related costs
|
|
|
(5,087)
|
|
|
(879)
|
|
|
(12,245)
|
|
|
(3,829)
|
Impairment of assets
held-for-sale
|
|
|
(15,926)
|
|
|
—
|
|
|
(21,963)
|
|
|
—
|
Impact of business
held-for-sale2)
|
|
|
447
|
|
|
—
|
|
|
525
|
|
|
—
|
Operating
income
|
|
$
|
45,822
|
|
$
|
94,525
|
|
$
|
206,686
|
|
$
|
298,944
|
|
1) Includes the quarterly results of
the partially-owned consolidated subsidiary prior to the sale of
this partially-owned consolidated subsidiary to a third party in
the first fiscal quarter of 2023.
|
2) Since December 31, 2023, the
Company has a business that has met the held-for-sale criteria. For
the quarter ended June 30, 2024, includes the results for the
three-months ended for this business held-for-sale. For the year
ended June 30, 2024, includes the six-month results of this
business held-for-sale for the period starting December 31, 2023
through June 30, 2024 while the business has met the held-for-sale
criteria.
|
BIO-TECHNE CORPORATION
|
RECONCILIATION OF GAAP
NET INCOME TO ADJUSTED EBITDA
|
(In
thousands)
|
(Unaudited)
|
|
|
QUARTER
|
|
YEAR
|
|
ENDED
|
|
ENDED
|
|
6/30/2024
|
|
6/30/2023
|
|
6/30/2024
|
|
6/30/2023
|
Net earnings
attributable to Bio-Techne
|
$
|
40,587
|
|
$
|
75,484
|
|
$
|
168,105
|
|
$
|
285,263
|
Net interest expense
(income)
|
|
1,605
|
|
|
2,668
|
|
|
12,413
|
|
|
7,805
|
Depreciation and
amortization
|
|
28,057
|
|
|
26,923
|
|
|
111,711
|
|
|
107,238
|
Income
taxes
|
|
1,073
|
|
|
12,832
|
|
|
17,584
|
|
|
53,217
|
EBITDA attributable to
Bio-Techne
|
|
71,322
|
|
|
117,907
|
|
|
309,813
|
|
|
453,523
|
Costs recognized upon
sale of acquired inventory
|
|
179
|
|
|
—
|
|
|
729
|
|
|
400
|
Acquisition related
expenses and other
|
|
4,955
|
|
|
(477)
|
|
|
7,564
|
|
|
(9,147)
|
Certain litigation
charges
|
|
3,506
|
|
|
—
|
|
|
3,506
|
|
|
—
|
Amortization of Wilson
Wolf intangible assets and acquired inventory
|
|
3,062
|
|
|
2,805
|
|
|
15,686
|
|
|
2,805
|
Gain on sale of
partially-owned consolidated subsidiaries
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11,682)
|
Stock-based
compensation, inclusive of employer taxes
|
|
7,466
|
|
|
(1,662)
|
|
|
40,277
|
|
|
41,217
|
Restructuring and
restructuring-related costs
|
|
5,087
|
|
|
879
|
|
|
12,245
|
|
|
3,829
|
Investment (gain) loss
and other non-operating
|
|
0
|
|
|
682
|
|
|
(283)
|
|
|
(37,646)
|
Impairment of assets
held-for-sale
|
|
15,926
|
|
|
—
|
|
|
21,963
|
|
|
—
|
Impact of business
held-for-sale2)
|
|
(447)
|
|
|
—
|
|
|
(525)
|
|
|
—
|
Impact of
partially-owned consolidated subsidiaries1)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(241)
|
Adjusted
EBITDA
|
$
|
111,056
|
|
$
|
120,134
|
|
$
|
410,975
|
|
$
|
443,058
|
|
1) Net
earnings attributable to Bio-Techne excludes non-controlling
interest of approximately 43% of the GAAP net earnings or loss for
Eminence. To prevent double-counting the non-controlling interest
component within our Adjusted EBITDA calculation, the amount
accounts for both the non-controlling interest within the GAAP
metric and the impact of partially-owned consolidated subsidiaries
within our Non-GAAP adjusted consolidated net earnings
table.
|
2) Since December 31, 2023, the
Company has a business that has met the held-for-sale criteria. For
the quarter ended June 30, 2024, includes the results for the
three-months ended for this business held-for-sale. For the year
ended June 30, 2024, includes the six-month results of this
business held-for-sale for the period starting December 31, 2023
through June 30, 2024 while the business has met the held-for-sale
criteria.
|
BIO-TECHNE CORPORATION
|
CONDENSED CASH
FLOW
|
(In
thousands)
|
(Unaudited)
|
|
|
|
YEAR
|
|
|
ENDED
|
|
|
6/30/2024
|
|
6/30/2023
|
CASH FLOWS FROM
OPERATING ACTIVITIES
|
|
|
|
|
|
|
Net earnings
|
|
$
|
168,105
|
|
$
|
285,442
|
Adjustments to
reconcile net earnings to net cash provided by operating
activities
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
111,711
|
|
|
107,238
|
Costs recognized on
sale of acquired inventory
|
|
|
729
|
|
|
400
|
Deferred income
taxes
|
|
|
(39,447)
|
|
|
(29,567)
|
Stock-based
compensation expense
|
|
|
38,042
|
|
|
39,230
|
Gain on sale of CCXI
investment
|
|
|
—
|
|
|
(37,176)
|
Fair value adjustment
to available-for-sale investments
|
|
|
(283)
|
|
|
(472)
|
Loss on equity method
investment
|
|
|
6,841
|
|
|
1,143
|
Asset impairment
restructuring
|
|
|
2,634
|
|
|
—
|
Fair value adjustment
to contingent consideration payable
|
|
|
(3,500)
|
|
|
(12,100)
|
Gain on sale of
Eminence
|
|
|
—
|
|
|
(11,682)
|
Impairment of assets
held-for-sale
|
|
|
21,963
|
|
|
—
|
Other operating
activities
|
|
|
(7,814)
|
|
|
(88,063)
|
Net cash provided by
(used in) operating activities
|
|
|
298,981
|
|
|
254,393
|
CASH FLOWS FROM
INVESTING ACTIVITIES
|
|
|
|
|
|
|
Proceeds from sale of
available-for-sale investments
|
|
|
28,083
|
|
|
35,236
|
Purchases of
available-for-sale investments
|
|
|
(5,526)
|
|
|
(20,500)
|
Proceeds from sale of
CCXI investment
|
|
|
—
|
|
|
73,219
|
Additions to property
and equipment
|
|
|
(62,877)
|
|
|
(38,244)
|
Acquisitions, net of
cash acquired
|
|
|
(169,707)
|
|
|
(101,184)
|
Distributions from
(Investments in) Wilson Wolf
|
|
|
6,997
|
|
|
(232,000)
|
Proceeds from sale of
Eminence
|
|
|
—
|
|
|
17,824
|
Net cash provided by
(used in) investing activities
|
|
|
(203,030)
|
|
|
(265,649)
|
CASH FLOWS FROM
FINANCING ACTIVITIES
|
|
|
|
|
|
|
Cash
dividends
|
|
|
(50,419)
|
|
|
(50,285)
|
Proceeds from stock
option exercises
|
|
|
60,935
|
|
|
29,813
|
Long-term debt
activity, net
|
|
|
(31,000)
|
|
|
94,000
|
Re-purchases of common
stock
|
|
|
(80,042)
|
|
|
(19,562)
|
Taxes paid on RSUs and
net share settlements
|
|
|
(21,872)
|
|
|
(28,893)
|
Other financing
activity
|
|
|
—
|
|
|
(2,457)
|
Net cash provided by
(used in) financing activities
|
|
|
(122,398)
|
|
|
22,616
|
Effect of exchange rate
changes on cash and cash equivalents
|
|
|
(2,333)
|
|
|
(3,356)
|
Net increase (decrease)
in cash and cash equivalents
|
|
|
(28,780)
|
|
|
8,004
|
Cash and cash
equivalents at beginning of period
|
|
|
180,571
|
|
|
172,567
|
Cash and cash
equivalents at end of period
|
|
$
|
151,791
|
|
$
|
180,571
|
![BT Logo (PRNewsfoto/Bio-Techne Corporation) BT Logo (PRNewsfoto/Bio-Techne Corporation)](https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-fourth-quarter-fiscal-2024-results-302216424.html
SOURCE Bio-Techne Corporation